Canada markets closed

WPD Pharmaceuticals Inc. (WPDPF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2070+0.0002 (+0.11%)
At close: 9:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.2068
Open0.2070
BidN/A x N/A
AskN/A x N/A
Day's Range0.2070 - 0.2070
52 Week Range0.2070 - 0.2070
Volume500
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • WPD Pharmaceuticals Receives Approval for Temporary Management Cease Trade Order for Late Filing of Audited Annual Financial Statements
    GlobeNewswire

    WPD Pharmaceuticals Receives Approval for Temporary Management Cease Trade Order for Late Filing of Audited Annual Financial Statements

    VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company”) (CSE: WBIO) (FSE: 8SV1), announces that further to its news release dated April 29, 2021 it has received approval from the British Columbia Securities Commission for a temporary management cease trade order (“MCTO”) under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”), which prohibits trading in securities of the Company by certain insiders of the Company, whether direct or indirect. The Company required the MCTO as it was unable to file its Annual Filings within the deadline as required under National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”). The MCTO is not expected to have any effect on trading in the Company’s shares by the public. The Company anticipates that it will be a position to file the Annual Filings on or about May 10, 2021. The MCTO will be in effect until the Annual Filings are filed. The Company confirms that it will comply with the alternative information guidelines included in NP 12-203 so long as the Annual Filings are outstanding. About WPD Pharmaceuticals WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland. WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 31 countries in Europe and Asia, including Russia. On Behalf of the Board ‘Mariusz Olejniczak’ Mariusz OlejniczakCEO, WPD Pharmaceuticals Contact Investor RelationsEmail: investors@wpdpharmaceuticals.comTel: 604-428-7050Web: www.wpdpharmaceuticals.com Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release. This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company can file its Annual Filings on or before May 10, 2021 and can develop effective drugs against cancer and possibly viruses. Factors which may prevent the forward looking statement from being realized include that our auditors may not be able to complete their audit by May 10, 2021; competitors or others may successfully challenge a granted patent and the patent could be rendered void; we may be unable to raise sufficient funding for our research; we may be unable to expend sufficient funds on research to keep our sublicense rights; our grant applications may not be successful or if successful, we may not meet the requirements to receive the grants awarded; that our drugs don’t provide positive treatment, or if they do, the side effects are damaging; competitors may develop better or cheaper drugs; and we may be unable to obtain regulatory approval for any drugs we develop; the filing of the Annual Filings and the projected timing. Readers should refer to the risk disclosure included from time-to-time in the documents the Company files on SEDAR, available at www.sedar.com. Although the Company believes that the assumptions inherent in these forward-looking statements are reasonable, they are not guarantees of future performance and, accordingly, they should not be relied upon and there can be no assurance that any of them will prove to be accurate. Finally, these forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update them except as required by applicable law.

  • WPD Pharmaceuticals Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements
    GlobeNewswire

    WPD Pharmaceuticals Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements

    VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company”) (CSE: WBIO) (FSE: 8SV1), the Company announces that it has made an application to the British Columbia Securities Commission to approve a temporary management cease trade order (“MCTO”) under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”), which, if granted, will prohibit trading in securities of the Company by certain insiders of the Company, whether direct or indirect. The Company is seeking the MCTO as it is unable to file it Annual Filings (as defined below) within the deadline as required under National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”). The Company anticipates that it will be a position to file the Annual Filings on or about May 10, 2021. The MCTO will be in effect until the Annual Filings are filed. The Company confirms that it will comply with the alternative information guidelines included in NP 12-203 so long as the Annual Filings are outstanding. About WPD Pharmaceuticals WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland. WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 31 countries in Europe and Asia, including Russia. On Behalf of the Board ‘Mariusz Olejniczak’ Mariusz OlejniczakCEO, WPD Pharmaceuticals Contact Investor RelationsEmail: investors@wpdpharmaceuticals.comTel: 604-428-7050Web: www.wpdpharmaceuticals.com Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release. This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company can develop effective drugs against cancer and possibly viruses. Factors which may prevent the forward looking statement from being realized include that competitors or others may successfully challenge a granted patent and the patent could be rendered void; we may be unable to raise sufficient funding for our research; we may be unable to expend sufficient funds on research to keep our sublicense rights; our grant applications may not be successful or if successful, we may not meet the requirements to receive the grants awarded; that our drugs don’t provide positive treatment, or if they do, the side effects are damaging; competitors may develop better or cheaper drugs; and we may be unable to obtain regulatory approval for any drugs we develop; the filing of the Annual Filings and the projected timing. Readers should refer to the risk disclosure included from time-to-time in the documents the Company files on SEDAR, available at www.sedar.com. Although the Company believes that the assumptions inherent in these forward-looking statements are reasonable, they are not guarantees of future performance and, accordingly, they should not be relied upon and there can be no assurance that any of them will prove to be accurate. Finally, these forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update them except as required by applicable law.

  • WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas
    GlobeNewswire

    WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas

    VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it will attend the 10th Annual Congress of the Polish Society of Pediatric Oncology and Hematology to be held on May 6-8, 2021. During the Congress, WPD will present the key assumptions of the WPD-201P Clinical Trial Protocol, which is planned to start in Q2 2021, as a part of the research project: “New approach to glioblastoma treatment addressing the critical unmet medical need“, granted by National Research and Development Center (“NRDC”) and co-financed by the European Union, under the Smart Growth Operational Program 2014-2020. Berubicin is a second-generation anthracycline candidate for the treatment of a number of Central Nervous System Cancers, including Glioblastoma Multiforme (GBM) and Malignant Gliomas. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin was developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center, and demonstrated positive responses that include one durable complete response in a Phase 1 human clinical trial conducted previously by Reata Pharmaceuticals, Inc. Mariusz Olejniczak, CEO of WPD commented, “We are very excited for the ability to share our Phase I pediatric clinical trial protocol with the members of the pediatric oncology society. This will be a great opportunity to promote our project and to establish the possibility for future cooperation.” WPD also announces it has engaged Strikepoint Media LLC. (“Strikepoint”), to provide digital marketing and brand awareness support. The Company has agreed to pay Strikepoint US$50,000 for a 3 month digital media term commencing on April 26, 2021. Strikepoint will not receive any securities of the Company as compensation for their services. About WPD Pharmaceuticals WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland. WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 30 countries in Europe and Asia, including Russia. On Behalf of the Board ‘Mariusz Olejniczak’ Mariusz Olejniczak CEO, WDP Pharmaceuticals Contact: Email: investors@wpdpharmaceuticals.com Tel: 604-428-7050 Web: www.wpdpharmaceuticals.com Investor Relations: Arrowhead Business and Investment Decisions, LLC Thomas Renaud Managing Director 42 Broadway, 17th Floor New York, NY 10004 Office: +1 212 619-6889 enquire@arrowheadbid.com Cautionary Statements: Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release. This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company anticipates will or may occur in the future. Forward-looking statements in this press release include that we can access the remainder of our NCRD grants and that WPD’s drugs could be developed into novel treatments for cancer. These forward-looking statements reflect the Company’s current expectations based on information currently available to management and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those projected. Factors which may prevent the forward looking statement from being realized is that competitors or others may successfully challenge a granted patent and the patent could be rendered void; that we are unable to raise sufficient funding for our research; that we may not meet the requirements to receive the grants awarded; that our drugs don’t provide positive treatment, or if they do, the side effects are damaging; competitors may develop better or cheaper drugs; and we may be unable to obtain regulatory approval for any drugs we develop. Readers should refer to the risk disclosure included from time-to-time in the documents the Company files on SEDAR, available at www.sedar.com. Although the Company believes that the assumptions inherent in these forward-looking statements are reasonable, they are not guarantees of future performance and, accordingly, they should not be relied upon and there can be no assurance that any of them will prove to be accurate. Finally, these forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update them except as required by applicable law.